株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙SALE
市場調査レポート

アルツハイマー病治療薬の世界市場:2017年〜2021年

Global Alzheimer's Drugs Market 2017-2021

発行 TechNavio (Infiniti Research Ltd.) 商品コード 273286
出版日 ページ情報 英文 102 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.24円で換算しております。
Back to Top
アルツハイマー病治療薬の世界市場:2017年〜2021年 Global Alzheimer's Drugs Market 2017-2021
出版日: 2017年07月12日 ページ情報: 英文 102 Pages
概要

世界のアルツハイマー病治療薬市場は、2017年から2021年にかけて、1.90%の複合年間成長率 (CAGR) で拡大する見通しです。

当レポートでは、世界におけるアルツハイマー病治療薬市場の現況とその成長予測、主要医薬品の評価、ベンダーの情報などを提供しています。

第1章 エグゼクティブサマリー

第2章 当レポートの調査範囲

第3章 調査手法

第4章 イントロダクション

  • 市場概要

第5章 アルツハイマー病の概要

第6章 市場情勢

  • 市場概要
  • 市場規模と予測
  • ファイブフォース分析

第7章 パイプラインの状況

第8章 作用機序別の市場分類

  • アセチルコリンエステラーゼ (AChE) 阻害薬
  • グルタミン酸阻害薬

第9章 FDA認証薬の市場評価

  • Aricept
  • Exelon
  • NAMENDA
  • Razadyne

第10章 地理区分

  • 南北アメリカ
  • 欧州・中東・アフリカ地域
  • アジア太平洋地域

第11章 意思決定の枠組み

第12章 市場の成長因子と課題

  • 市場成長因子
  • 市場の課題

第13章 市場動向

第14章 ベンダー情勢

  • 競合シナリオ

第15章 主要ベンダーの分析

  • ALLERGAN
  • エーザイ
  • Johnson & Johnson
  • Novartis
  • その他の有力ベンダー

第16章 付録

  • 略語リスト

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: IRTNTR13693

About Alzheimer's Drugs

Alzheimer's disease is a progressive and irreversible degeneration of the brain that disrupts the thinking, language, behavior, and cognitive skills of a person. It is more prevalent in people aged 65 years and above and affects more women than men. As per the Centers for Disease Control and Prevention (CDC), 5.4 million Americans are affected by this disease, and the incidence rate of disease increases with age and doubles every five years for adults beyond 65 years of age.

Technavio's analysts forecast the global alzheimer's drugs market to grow at a CAGR of 1.90% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global alzheimer's drugs market for 2017-2021. To calculate the market size, the report considers the sales of branded, generic, and off-label drugs.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Alzheimer's Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • ALLERGAN
  • Eisai Pharmaceuticals
  • Johnson & Johnson
  • Novartis

Other Prominent Vendors

  • Amgen
  • Pfizer

Market driver

  • Appropriate strategies designed to increase public awareness
  • For a full, detailed list, view our report

Market challenge

  • Social stigma associated with Alzheimer's disease
  • For a full, detailed list, view our report

Market trend

  • Reformulation of marketed drugs
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

  • Market outline

PART 05: Alzheimer's disease: An overview

  • National Alzheimer's Project

PART 06: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 07: Pipeline landscape

PART 08: Market segmentation by MoA

  • AChE inhibitors
  • Glutamate inhibitors

PART 09: Market assessment of FDA-approved drugs

  • Aricept
  • Exelon
  • NAMENDA
  • Razadyne

PART 10: Geographical segmentation

  • Alzheimer's drugs market in Americas
  • Alzheimer's drugs market in EMEA
  • Alzheimer's drugs market in APAC

PART 11: Decision framework

PART 12: Drivers and challenges

  • Market drivers
  • Market challenges

PART 13: Market trends

  • Rising government initiatives to support Alzheimer's disease
  • Rising burden of Alzheimer's disease
  • Reformulation of marketed drugs

PART 14: Vendor landscape

  • Competitive scenario

PART 15: Key vendor analysis

  • ALLERGAN
  • Eisai Pharmaceuticals
  • Johnson & Johnson
  • Novartis
  • Other prominent vendors

PART 16: Appendix

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Alzheimer disease: A brief overview
  • Exhibit 02: Progression of Alzheimer's disease
  • Exhibit 03: Mechanism of pathogenesis of Alzheimer's disease
  • Exhibit 04: Risk factors responsible for development of Alzheimer's disease
  • Exhibit 05: Alzheimer's disease treatment: Milestones
  • Exhibit 06: Vendor's initiative for promoting Alzheimer's drugs business
  • Exhibit 07: Global Alzheimer's drugs market: Snapshot
  • Exhibit 08: Global Alzheimer's drugs market 2016-2021 ($ millions)
  • Exhibit 09: Opportunity analysis of global Alzheimer's drugs market
  • Exhibit 10: Five forces analysis
  • Exhibit 11: Pipeline snapshot based on number of molecules
  • Exhibit 12: Key clinical trials
  • Exhibit 13: Alzheimer's drugs with fast track designation
  • Exhibit 14: Market segmentation based on MoA
  • Exhibit 15: Global Alzheimer's drugs market share based on MoA
  • Exhibit 16: Global Alzheimer's AChE inhibitors drugs market 2016-2021 ($ millions)
  • Exhibit 17: Global Alzheimer's glutamate inhibitors drugs market 2016-2021 ($ millions)
  • Exhibit 18: FDA-approved drugs for the treatment of Alzheimer's disease
  • Exhibit 19: Key events timeline for Aricept formulations in Japan
  • Exhibit 20: Key events timeline for Aricept in US and Europe
  • Exhibit 21: Exelon revenue 2015 and 2016 ($ millions)
  • Exhibit 22: Key events timeline for Exelon formulation
  • Exhibit 23: NAMENDA revenue 2015 and 2016 ($ millions)
  • Exhibit 24: Key events timeline for NAMENDA
  • Exhibit 25: Razadyne revenue 2015 and 2016 ($ millions)
  • Exhibit 26: Key events timeline for Razadyne
  • Exhibit 27: Global Alzheimer's drugs market share by geography 2016 and 2021
  • Exhibit 28: Global Alzheimer's drugs market revenue by geography 2016-2021
  • Exhibit 29: Alzheimer's drugs market scenario in different geographies
  • Exhibit 30: Market scenario in Americas
  • Exhibit 31: Alzheimer's drugs market in Americas 2016-2021 ($ millions)
  • Exhibit 32: Market scenario in EMEA
  • Exhibit 33: Alzheimer's drugs market in EMEA 2016-2021 ($ millions)
  • Exhibit 34: Market scenario in APAC
  • Exhibit 35: Alzheimer's drugs market revenue in APAC 2016-2021 ($ millions)
  • Exhibit 36: Death rate per 100,000 of US population due to Alzheimer's disease 2010-2014
  • Exhibit 37: Revenue erosion of Aricept after loss of exclusivity
  • Exhibit 38: Estimated number of people aged 65 and older with Alzheimer's disease in the US, 2010-2050
  • Exhibit 39: Competitive structure analysis of global Alzheimer's drugs market 2016
  • Exhibit 40: ALLERGAN: Key highlights
  • Exhibit 41: ALLERGAN: Strength assessment
  • Exhibit 42: ALLERGAN: Strategy assessment
  • Exhibit 43: ALLERGAN: Opportunity assessment
  • Exhibit 44: Eisai Pharmaceuticals: key highlights
  • Exhibit 45: Eisai Pharmaceuticals: Strength assessment
  • Exhibit 46: Eisai Pharmaceuticals: Strategy assessment
  • Exhibit 47: Eisai Pharmaceuticals: Opportunity assessment
  • Exhibit 48: Johnson & Johnson: Key highlights
  • Exhibit 49: Johnson & Johnson: Strength assessment
  • Exhibit 50: Johnson & Johnson: Strategy assessment
  • Exhibit 51: Johnson & Johnson: Opportunity assessment
  • Exhibit 52: Novartis: Key highlights
  • Exhibit 53: Novartis: Strength assessment
  • Exhibit 54: Novartis: Strategy assessment
  • Exhibit 55: Novartis: Opportunity assessment
Back to Top